[1]贾俊.红花注射抗血栓药效物质基础初步研究[D].太原:山西大学, 2010.

[2]Martine Gilard, Paul Barragan, Arif A L Noryani.6- versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: the randomized, multicenter ITALIC trial[J].J Am coll cardiol, 2015, 65(8):777-786.

[3]周铭.血小板聚集功能的检测——光谱学及软X线成像研究[D].合肥：安徽医科大学, 2016.

[4]王晓锋,陈乃宏,王文.抗血小板聚集药物的机制研究进展[J].中国康复理论与实践, 2010, 16(10): 954-957.

[5]Shaturny? V I, Shakhidzhanov SS, Sveshnikova AN, Panteleev MA.Activators, receptors and signal transduction pathways of blood platelets[J]. Biomed Khim. 2014, 60(2):182-200

[6]Liu Yang-yang, Hu Meng-jiao. Luo Dong-jiao,et al.Class III PI3K Positively Regulates Platelet Activation and Thrombosis via PI(3)P-Directed Function of NADPH Oxidase[J]. Arterioscler Thromb Vasc Biol, 2018, 38(3): e26-e27.

[7]Zoubir Djerada, Catherine Feliu, Vincent Richard.Current knowledge on the role of P2Y receptors in cardioprotection against ischemia-reperfusion[J]. Pharmacol Res, 2017, 118: 5-18.

[8]陆四,孟照辉.血小板膜蛋白受体信号转导通路的研究进展[J].医学综述, 2014, 20(21): 3851-3854.

[9] Atkinson L, Yusuf1 M.Z, Aburima A,et al.Reversal of stress fibre formation by Nitric Oxide mediated RhoA inhibition leads to reduction in the height of preformed thrombi[J]. Sci Rep, 2018, 8(1):3032

[10] Yusuf M Z, Raslan Z, Atkinson L,et al.Prostacyclin reverses platelet stress fibre formation causing platelet aggregate instability[J]. Scientific, 2017, 7(1): 5582

[11]Wu Chin-chung, Teng Che-ming.Comparison of the effects of PAR1 antagonists, PAR4 antagonists, and their combinations on thrombin-induced human platelet activation[J]. Eur J Pharmacol, 2006, 546(1-3): 142-47.

[12]余果宇，张勇，江萍.蛋白酶激活受体[J].生命的化学, 2011, 31(03): 425-428.

[13] Beatrice Hechler, Christian Gachet.P2 receptors and platelet function［J］. Purinergic Signal, 2011, 7(3): 293-303

[14]Pia R M Siljander, Imke C A Munnix, Peter A Smethurst,et al.Platelet receptor interplay regulates collagen-induced thrombus formation in flowing human blood[J]. Blood, 2004, 103(4): 1333-1341.

[15]Jane F Arthur, Elizabeth Gardiner, Maria Matzaris,et al.Glycoprotein VI is associated with GPIb-IX-V on the membrane of resting and activated platelets[J]. Thromb Haemost, 2005, 93(4): 716-23.

[16]李雪晴,耿婷.血小板活化因子(PAF)受体拮抗剂的研究进展[J].中国中药杂志, 2018, 24(04): 1392-1403

[17] Federico Iovino, Matthijs C Brouwer, Diederik van de Beek,et al.Signalling or binding: the role of the platelet-activating factor receptor in invasive pneumococcal disease[J]. Cell Microbiol, 2013, 15(6): 870-881

[18] Omair Yousuf, Deepak L Bhatt.The evolution of antiplatelet therapy in cardiovascular disease[J]. Nat Rev Cardiol, 2011, 8(10): 547-59.

[19]Gu X, Fu X, Wang Y,et al. Comparison of ticagrelor and high-dose clopidogrel on the platelet functions in patients with inadequate response to clopidogrel [J]. Am J Cardiovasc Dis, 2017, 7(1):1-8

[20]董慧宇,陈献华. P2Y12受体拮抗剂类抗血小板药物的研究新进展[J].中国新药杂志，2017, 26(12):1406-1411

[21] Beatrice Hechler, Christelle Nonne, Eun Joo Roh,et al.MRS2500 [2-iodo-N6-methyl-(N)-methanocarba-2'-deoxyadenosine-3',5'-bisphosphate], a potent, selective, and stable antagonist of the platelet P2Y1 receptor with strong antithrombotic activity in mice[J]. J Pharmacol Exp Ther, 2006, 316(2): 556-63.

[22] Maree A O, Cox D, Fitzgerald D J.Drug insight: aspirin resistance-fact or fashion? [J]. Nat Clin Pract Cardiovasc Med, 2007, 4(3): E1

[23] Xu Li-na, Yu Wen-gui, Tian Jin-ying,et al.Effectof sodium ferulate on arachidonic acid metabolism[J]. Acta Pharm Sin, 1990, 25(6) : 412-416.

[24] Jantan I, Raweh S M, Sirat H M,et al.Inhibitory effect of compounds from Zingiberaceae species on human platelet aggregation[J].Phytomedicine, 2008, 15(4): 306-309

[25] Marilena Crescente, Gisela Jessen, Stefania Momi,et al.Interactions of gallic acid, resveratrol, quercetin and aspirin at the platelet cycloox-ygenase-1 level. Functional and modelling studies[J]. Thromb Haemost, 2009, 102(2): 336-346.

[26]张林山. PAR-1受体拮抗剂E5555类似物的研究[D].青岛:青岛科技大学，2012.

[27] Shinya Goto, Testu Yamaguchi, Yasuo Ikeda,et al.Safety and exploratory efficacy of the novel thrombin receptor(PAR-1) antagonist SCH530348 for non-ST-segment elevation acute coronary syndrome[J]. J Atheroscler. Thromb, 2010, 17 (2): 156-164.

[28] Jennifer Vergara-Jimenez, Pierluigi Tricoci.Safety and efficacy of abciximab as an adjunct to percutaneous coronary intervention[J]. Vasc Health Risk Manag, 2010, 6: 39-45.

[29]陈俞宏,李孝成.低分子肝素结合替罗非班治疗老年急性下肢深静脉血栓对PAC-1、P选择素的影响[J].中国现代医学杂志, 2018, 28(03): 64-68

[30]高稳,李健.EＲK5对体外血小板活化及在体血栓的影响[J].中国病理生理杂志, 2017, 33(11): 1958-1963

[31]Li Wei, Yue Hong.Thymidine phosphorylase: A potential new target for treating cardiovascular disease[J]. Science Direc, 2018, 28(3): 157-171

[32]Diana A Gorog, Zahi A Fayad, Valentin Fuster.Arterial thrombus stability: does it matter and can we detect it? [J]. J Am Coll Cardiol, 2017, 70(16): 2036–2047.